Zapata, Luis http://orcid.org/0000-0002-1386-2019
Caravagna, Giulio http://orcid.org/0000-0003-4240-3265
Williams, Marc J. http://orcid.org/0000-0001-5524-4174
Lakatos, Eszter http://orcid.org/0000-0002-7221-6850
AbdulJabbar, Khalid
Werner, Benjamin http://orcid.org/0000-0002-6857-8699
Chowell, Diego
James, Chela
Gourmet, Lucie
Milite, Salvatore
Acar, Ahmet
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Graham, Trevor A. http://orcid.org/0000-0001-9582-1597
Sottoriva, Andrea http://orcid.org/0000-0001-6709-9533
Article History
Received: 27 October 2021
Accepted: 25 January 2023
First Online: 9 March 2023
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C. and D.C. hold ownership of intellectual property on using tumor mutational burden to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. The other authors declare no competing interests.